iMDx and ASTS Fund $100K Study on In-House vs. Outsourced Transplant Testing — Insight Molecular Diagnostics Inc. (iMDx)

Event summary

$100,000 grant awarded to study health economics of in-house vs. send-out dd-cfDNA testing for kidney transplants.
Recipients: Kenneth Andreoni (Thomas Jefferson University) and Kenneth Chavin (Temple Health).
Research will compare costs, clinical impact, and operational implications of in-house diagnostic testing versus centralized lab testing.
Results to support commercialization planning for GraftAssureDx™, currently under FDA review.

The big picture

The grant underscores a growing industry shift toward in-house diagnostic testing for kidney transplants, driven by demands for faster results and better patient outcomes. As more centers adopt dd-cfDNA testing, rigorous economic data will be critical in guiding investment decisions. The study's findings could influence the broader adoption of molecular diagnostics in transplant care, potentially reshaping lab infrastructure strategies across the field.

What we're watching

Regulatory Timelines: The pace at which the FDA reviews GraftAssureDx™ will determine iMDx's commercialization strategy.
Market Adoption: Whether transplant centers prioritize in-house testing for faster turnaround times and improved patient care.
Economic Viability: How the study's findings impact the cost-benefit analysis for transplant programs considering in-house diagnostics.